Embecta (NASDAQ:EMBC) Upgraded to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Embecta (NASDAQ:EMBC) from a buy rating to a strong-buy rating in a research report report published on Saturday.

A number of other equities research analysts also recently commented on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. BTIG Research reaffirmed a “buy” rating and issued a $25.00 target price on shares of Embecta in a research note on Friday, February 6th. One investment analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $18.50.

Embecta Stock Performance

Embecta stock opened at $9.07 on Friday. Embecta has a fifty-two week low of $9.06 and a fifty-two week high of $15.55. The company has a market capitalization of $537.13 million, a price-to-earnings ratio of 3.83 and a beta of 1.10. The stock has a fifty day moving average of $11.08 and a two-hundred day moving average of $12.75.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Thursday, February 5th. The company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.04. The business had revenue of $261.20 million for the quarter, compared to the consensus estimate of $258.07 million. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The business’s revenue was down .3% on a year-over-year basis. During the same period in the prior year, the business earned $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. On average, analysts forecast that Embecta will post 2.85 EPS for the current fiscal year.

Embecta Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 17th. Investors of record on Friday, February 27th will be issued a $0.15 dividend. The ex-dividend date is Friday, February 27th. This represents a $0.60 dividend on an annualized basis and a yield of 6.6%. Embecta’s dividend payout ratio (DPR) is 25.32%.

Institutional Investors Weigh In On Embecta

Hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada grew its position in shares of Embecta by 38.3% during the first quarter. Royal Bank of Canada now owns 18,201 shares of the company’s stock worth $232,000 after buying an additional 5,036 shares in the last quarter. AQR Capital Management LLC grew its holdings in Embecta by 3.7% during the 1st quarter. AQR Capital Management LLC now owns 225,641 shares of the company’s stock worth $2,738,000 after acquiring an additional 8,109 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Embecta by 2.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock valued at $629,000 after purchasing an additional 1,159 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Embecta by 4.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company’s stock valued at $2,195,000 after purchasing an additional 7,894 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Embecta by 224.0% during the 1st quarter. Jane Street Group LLC now owns 132,688 shares of the company’s stock worth $1,692,000 after purchasing an additional 91,729 shares during the last quarter. Institutional investors and hedge funds own 93.83% of the company’s stock.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.